We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Novartis has reached a preliminary agreement with CureVac to manufacture the mRNA and bulk drug product for the latter’s Covid-19 vaccine candidate CVnCoV. The companies are currently under
UK-based AI-driven pharmatech Exscientia has closed $100m in a Series C investment round, joined by funds managed by BlackRock. The company’s existing investors including Novo Holdings, Evotec, Bristol
Pfizer has received the expanded US Food and Drug Administration (FDA) approval for Lorbrena (lorlatinib) to include treatment of a type of non-small cell lung cancer (NSCLC). The
Fujifilm Diosynth Biotechnologies (FDB), a contract development and manufacturing organisation (CDMO), has commenced the expansion of its large-scale cell culture facility in Denmark. The expansion project is anticipated
Royal Philips has partnered with AI-backed ultrasound applications provider DiA Imaging Analysis to provide clinicians with automated solutions at point-of-care. Under the partnership, DiA’s AI-powered automated solutions will
AGC Biologics, a US-based contract development and manufacturing organisation (CDMO), has unveiled its plans to expand its cell and gene therapy centre of excellence in Milan, Italy. With
Diagnostic testing solutions provider Quidel has secured the US Food and Drug Administration (FDA) Emergency Use Authorisation (EUA) to market its new QuickVue at-home Covid-19 test. The EUA
Memic has received the US Food and Drug Administration (FDA) De Novo marketing authorisation for its Hominis robot-assisted surgical platform. The De Novo authorisation facilitates the use of
Johnson & Johnson (J&J) has secured the US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its single-dose Covid-19 vaccine. Developed by J&J’s pharmaceutical subsidiary Janssen,
Roche has secured a special approval from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) for its SARS-CoV-2 Rapid Antigen Test for patient self-testing using nasal swab